These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25079804)

  • 21. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
    Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
    Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New and emerging treatments for Alzheimer's disease.
    Corbett A; Ballard C
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):147-56. PubMed ID: 22439621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint.
    Mani RB
    Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of new therapeutics for Alzheimer's disease.
    Carter MD; Simms GA; Weaver DF
    Clin Pharmacol Ther; 2010 Oct; 88(4):475-86. PubMed ID: 20811351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
    Chabrier PE
    Ann Pharm Fr; 2009 Mar; 67(2):97-103. PubMed ID: 19298893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coxibs and Alzheimer's disease: should they stay or should they go?
    Firuzi O; Praticò D
    Ann Neurol; 2006 Feb; 59(2):219-28. PubMed ID: 16402383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?
    Francis PT; Nordberg A; Arnold SE
    Trends Pharmacol Sci; 2005 Feb; 26(2):104-11. PubMed ID: 15681028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease.
    Haas C
    J Alzheimers Dis; 2012; 28(2):241-81. PubMed ID: 21987594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
    Munoz L; Ammit AJ
    Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early clinical trials in Alzheimer's disease: selection and evaluation of drug candidates.
    Reines SA
    Prog Clin Biol Res; 1989; 317():1283-90. PubMed ID: 2690095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers in preclinical Alzheimer's disease.
    Chong MS; Lim WS; Sahadevan S
    Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
    Gauthier S; Leuzy A; Rosa-Neto P
    Neurodegener Dis; 2014; 13(2-3):197-9. PubMed ID: 23942173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for Alzheimer's disease therapeutic trials.
    Hampel H; Wilcock G; Andrieu S; Aisen P; Blennow K; Broich K; Carrillo M; Fox NC; Frisoni GB; Isaac M; Lovestone S; Nordberg A; Prvulovic D; Sampaio C; Scheltens P; Weiner M; Winblad B; Coley N; Vellas B;
    Prog Neurobiol; 2011 Dec; 95(4):579-93. PubMed ID: 21130138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
    Ritchie CW; Russ TC; Banerjee S; Barber B; Boaden A; Fox NC; Holmes C; Isaacs JD; Leroi I; Lovestone S; Norton M; O'Brien J; Pearson J; Perry R; Pickett J; Waldman AD; Wong WL; Rossor MN; Burns A
    Alzheimers Res Ther; 2017 Oct; 9(1):85. PubMed ID: 29070066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The Need for a Trial Ready Cohort of Preclinical Alzheimer's Disease].
    Iwata A
    Brain Nerve; 2017 Jul; 69(7):757-762. PubMed ID: 28739989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroimaging outcomes in clinical trials in Alzheimer's disease.
    Frisoni GB; Delacourte A
    J Nutr Health Aging; 2009 Mar; 13(3):209-12. PubMed ID: 19262955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.